|
業務類別
|
Biotechnology |
|
業務概覽
|
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis. |
| 公司地址
| 2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037 |
| 電話號碼
| +1 858 240-1200 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.equilliumbio.com |
| 員工數量
| 14 |
| Dr. Stephen Connelly, PhD |
Chief Scientific Officer and President |
美元 455.17K |
15/04/2026 |
| Mr. Bruce D. Steel |
Director and Chief Executive Officer |
美元 519.23K |
15/04/2026 |
| Ms. Penny Tom |
Principal Accounting Officer and Senior Vice President, Finance |
-- |
25/03/2026 |
| Ms. Christine Zedelmayer |
Chief Operating Officer |
美元 441.29K |
15/04/2026 |
|
|
| Mr. Daniel M. Bradbury |
Chairman of the Board |
15/04/2026 |
| Dr. Mark Pruzanski, M.D. |
Independent Director |
15/04/2026 |
| Mr. Peter Colabuono |
Director |
15/04/2026 |
| Dr. Barbara Troupin, M.D. |
Independent Director |
15/04/2026 |
| Mr. Charles McDermott |
Independent Director |
15/04/2026 |
| Ms. Martha J. Demski |
Independent Director |
15/04/2026 |
| Mr. Bruce D. Steel |
Director and Chief Executive Officer |
15/04/2026 |
|
|
|
|
